Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe footer revision text changed from v3.6.3 to v3.6.4, indicating a new version of the site interface.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe record history now lists revision v3.6.3 as the current version, updating the page's metadata.SummaryDifference0.0%

- Check33 days agoChange DetectedThe page's revision label changed from v3.6.0 to v3.6.2. This reflects a new revision published in the history rather than a substantive change to content.SummaryDifference0.0%

- Check48 days agoChange DetectedThe history now shows that enrollment is closed ('No longer looking for participants'), adds a new revision entry 'Revision: v3.6.0', and removes the previous revision entry 'Revision: v3.5.5' from the record.SummaryDifference0.1%

- Check55 days agoChange DetectedThe page history now shows a new Revision: v3.5.5 tag, replacing the previous v3.5.4 tag, indicating a UI/version update in the history view.SummaryDifference0.0%

- Check76 days agoChange DetectedThe page history now includes a new revision tag, Revision: v3.5.4, replacing the previous Revision: v3.5.3. This reflects a minor update to the page's release version.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.